Nice's decision to withhold a breakthrough prostate cancer drug is a "cruel twist" as it comes "just days" after a study confirmed its success, campaigners have said.
Prostate Cancer UK called on Nice, who vet the cost effectiveness of medicine for NHS patients, to change its "post-chemo" policy on new drugs.
Enzalutamide is already licensed for those who've had chemotherapy but this trial will hopefully establish a robust base of evidence to demonstrate that it should be available beforehand.
This is good news but sadly won't help the one man an hour who dies of prostate cancer at present.
We need to see drugs like enzalutamide available sooner rather than later, and so it's a cruel twist that this study comes just days after Nice ruled out the drug for men who have already had chemotherapy and the only other drug available at this stage, abiraterone.
More top news
The RSPCA is being criticised over its new welfare standards which permit salmon farmers to kill seals that attack fish stocks.
The persistent Ebola infection that has re-hospitalised British nurse Pauline Cafferkey presents very little risk to others, an expert says.
A group of 'cereal offenders' have made off with £45,000 worth of Kellogg's breakfast bars after stealing a lorry full of the snacks.